ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 97.1% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -328.4% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -368.5% | – | – | – |
| EPS Diluted | -10.76 | -14.72 | -10.64 | -9.32 |
| % Growth | 26.9% | -38.3% | -14.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |